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Abstract Characterized by sudden episodes called seizures,
epilepsy was recognized long ago as a neurological disorder
that can have multiple forms ranging from benign to life
threatening depending upon its severity. Although several
evidences indicated that genes play an important role in at
least half of the patients, it is only with the advances in
molecular biology and genetics that the puzzle about
oligogenic and monogenic epilepsies slowly starts to unfold.
The finding of an association between a monogenic form of
epilepsy and a mutation in the gene encoding the neuronal
nicotinic acetylcholine receptor subunit CHRNA4 marked, in
1995, a turning point in our understanding of epilepsy. It also
marked the first step towards the today widely acknowl-
edged concept of epilepsies as channelopathies. Several
mutations in nicotinic acetylcholine receptor genes have,
since then, been identified, and the functional properties of
these mutated receptors were characterized. In this work, we
review, in the light of the latest discoveries, the effects
caused by the mutations on the physiological properties of
the receptors and the impact of such mutations on neuronal
network functions.
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Introduction
Already recognized as a brain disease by the Egyptians more
than 3,000 years ago, epilepsy is a rather common neurobi-
ological disorder that can be profoundly debilitating. Charac-
terized by sudden recurrent episodes termed seizure, epilepsy
ranges from benign to life threatening depending on the
severity and frequency of the seizure episodes. While there is
a general agreement that epilepsy is caused by hyper
synchrony of brain neuron firing, epilepsy can have multiple
origins and aspects depending upon the affected brain areas.
The average prevalence rate of epilepsy is about 1:100–200,
and most epilepsies are assumed to be caused by a
combination of acquired and genetic factors, many of them
still unknown. Predominantly genetic epilepsies constitute
only a minority of all seizure disorders but are of major
interest for science. Most of these monogenic epilepsies have
prevalence rates of 1:100,000 or less, but the apparently
straightforward relationship between an underlying mutation
and the clinical phenotype nevertheless made them a first-
choice tool to study the basic principles of epileptogenesis at a
molecular level. However, it is now acknowledged that even
in the apparently simple monogenic epilepsies, the discovery
of an underlying mutation not necessarily easily reveals the
pathophysiological pathway that leads from this specific
mutation to the clinically visible seizure. The complexity of
the mutation-phenotype relationship is best demonstrated by
the autosomal dominant nocturnal frontal lobe epilepsy
(ADNFLE), a rare seizure disorder that has been first
described about 15 years ago and studied intensively since
then. It would be difficult to find another genetic disorder in
which the known mutations are restricted to such a small part
of the gene but cause the same degree of functional and
clinical heterogeneity [14, 33, 37, 41, 48, 49]. ADNFLE not
only was the first human epilepsy for which a mutation had
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been described [49] but also allowed the first glimpse into
what turned out to be a major pathophysiological principle in
epileptogenesis. Caused by mutations in different subunits of
the neuronal nicotinic acetylcholine receptor (nAChR),
ADNFLE was the first seizure disorder for which the
importance of ion channels could be demonstrated. Other
monogenic epilepsies followed, establishing the concept of
epilepsies as channelopathies. Although some non-ion
channel mutations have been described recently, the chan-
nelopathy hypothesis remains the major pathogenic concept
in epilepsy research.
Autosomal dominant nocturnal frontal lobe epilepsy
The nocturnal clusters of brief motor seizures that are
typical for ADNFLE occur mostly out of non-rapid eye
movement sleep. Seizures are characterized by stereotyped
movements that can be preceded by an aura phenomenon
including epigastrial, sensory, or psychic symptoms. In
some patients, sleepwalking periods are common in which
they might move around and talk unintelligibly. Typically,
seizures start with gasps, grunts, or vocalizations followed
by thrashing hyperkinetic activity or tonic stiffening of the
limbs and superimposed clonic jerking. Patients are often
not aware of their seizures or they underestimate their
number of seizures per night. The clustering of seizures can
cause poor sleep quality, resulting in daytime fatigue.
Treatment with antiepileptic drugs such as carbamazepine
is often effective but in some patients fails to reduce seizure
frequency sufficiently. The seizures often start in the second
decade of life, but the age of onset can show considerable
intra- and interfamilial variation (first to sixth decade of
life). The seizure frequency tends to decline in middle age,
and long-lasting or complete remissions are sometimes
reported. Certain families display a pattern of clinical
symptoms that not only includes epileptic seizures but also
additional neurological features such as psychiatric disor-
ders, mental retardation, or cognitive dysfunction [4, 11,
35]. Most family's display an autosomal dominant pattern
of inheritance with reduced penetrance, less commonly, the
syndrome is caused by de novo mutations [41]. All but one
of the known mutations was found in either CHRNA4 or
CHRNB2, the genes coding for the α4- and β2-subunits of
the nAChR, respectively. An additional mutation was
described for the CHRNA2 gene in a family with a form
of sleep-related epilepsy that resembles ADNFLE [2].
Nicotinic acetylcholine receptors
First identified at the neuromuscular junction, nAChRs
belong to the large family of ligand-gated channels. Used
for a long time as a model of synaptic transmission, the
neuromuscular junction provided many clues about the
basic principles underlying chemical neurotransmission that
can be summarized as follows. Release of the neurotrans-
mitter in the synaptic cleft causes a brisk increase in
neurotransmitter concentration, which passively diffuses
through the extremely narrow extracellular space of the
synaptic cleft. Binding of the neurotransmitter on the
receptor causes the opening of ionic pores in the postsyn-
aptic membrane leading to the depolarization of the muscle
fiber up to its firing threshold. This mechanism provokes a
huge amplification factor allowing the propagation of the
nerve impulse from the motoneuron termination to the very
large muscle fiber. Although the basic principles of the
neurotransmission identified at the neuromuscular junction
provide a good framework for the functioning of brain
synapses, multiple differences in the functioning and
properties must also be considered when examining the
neurotransmission in the central nervous system.
The very high density and almost pseudocrystalline state
of nAChRs found in the Torpedo electro plaques provided
the first images with electron microscopic resolution of an
nAChR inserted in the postsynaptic membrane. Progresses
made from the early negative staining with high-resolution
microscopy yielded close to atomic resolution of the
receptor structure [52]. To date, however, the best models
yielding a resolution at near 2 Å come from the
acetylcholine binding protein for the extracellular domain
and from a cationic bacterial channel [8, 26]. Whilst data
have been collected from different species, they all point
out to the overall structure. Receptors result from the
assembly of five subunits arranged in a donut-like manner
around an axis of pseudosymmetry. Each subunit spans the
membrane four times with its N- and C-terminal ends
facing the extracellular domain. The extracellular domains
are arranged mainly in β-sheet, and the ligand-binding
pocket is formed at the interface between adjoining
subunits. Subunits presenting two adjacent cysteines in
their extracellular domain are termed α, whereas other
subunits are termed β (or γ, δ, and ε in the case of the
muscle receptors). The α subunits contribute to the
principal domain of the ligand-binding site, whereas β
subunits contribute to the complementary site. Located in
the center of such a pentamer, the ionic pore is bordered by
the second transmembrane segments comparable to the
staves of a barrel. The ionic selectivity and properties of the
pore are therefore governed by the amino acids facing this
central pore.
To date, 17 genes encoding for the muscle and neuronal
nAChRs have been identified and cloned in the mammalian
genome [1, 13]. The high degree of homology observed
across species together with the ancient age of nAChRs and
the diversity of subunits gained during evolution strongly
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indicate an important contribution to brain function. By
convention, genes encoding for the nAChR α subunits are
termed CHRNA1-10, whereas those encoding for β sub-
units are termed CHRNB1-4.
The simplest form of an nAChR is composed of five
identical subunits, such as in the homomeric α7 receptors.
Additional complexities in which two or more subunit types
are assembled in the same receptor are, however, widely
observed in the central and peripheral nervous system. A
prototype of such a receptor is the α4β2 which results from
the assembly of α4 and β2 subunits. While elegant
experiments initially suggested that a functional receptor
comprises two α4 and three β2 subunits [12], more recent
data suggest that α4β2 nAChRs may exist in different
stoichiometries [9, 38, 56]. As additional alternative α or β
subunits can be incorporated into such a receptor structure,
this gives rise to a large variety of receptor subtypes.
Although studies of native nAChRs became possible
with intracellular recordings in brain slices, most of the
physiological and pharmacological characterization of these
receptors was obtained by recombinant expression studies.
Important points demonstrated by these studies are the
possibility to examine the receptor properties in isolation
and to express human receptors as well as those from any
other species. Characterization of the α7 receptors revealed
that they are activated by high micromolar ranges of
acetylcholine (ACh) and display a very fast desensitization
during agonist exposure [23]. Another functional particu-
larity of the α7 receptor is its high calcium permeability
that was documented both in reconstituted and native
receptors [5, 19, 20, 22, 46]. By comparison, the hetero-
meric α4β2 nAChRs display a higher sensitivity to ACh,
slower desensitization, and lower calcium permeability [10,
45]. In addition, the α4β2 nAChRs show a dual phase in
the concentration activation curve [9]. As a consequence,
the receptor population can be divided in high and low
affinity ion channels, and effects of the ligand will depend
upon the fraction of receptors in either of these two states.
Interestingly, prolonged exposure to nicotine was shown to
change the ratio between high and low affinity indicating
that receptor properties and their apparent affinity for the
ligand can be modulated causing a change in the dynamic
range of the receptor responses [9]. Moreover, the presence
of high and low affinity components extents the dynamic range
in which the receptor responds to ACh. For the human α4β2
receptors, the high affinity component displays an EC50 (the
concentration causing the activation of half of the high
affinity receptor population) at about 3 μM, whereas the EC50
for the low affinity is at about 60 μM. By consequence, the
α4β2 receptor will respond to ACh concentrations ranging
from 0.1 to 300 μM or about three to four orders of
magnitude. By comparison, a receptor such as α7 displays a
dynamic range of about two orders of magnitude.
A biophysical characteristic shared by all neuronal
nAChRs, but not the muscle receptor, is a strong inward
rectification. The rectification is a (I-V) non-linear relation-
ship between transmembrane potential (V) and the current
flowing through the receptors (I). For transmembrane
potentials more negative than −40 mV, a current flows
through the receptors when they are activated, whereas the
current is profoundly reduced when the membrane is less
negative [3]. Rectification reflects the relationship between
the probability of channel opening and the voltage, whereas
the single channel conductance follows Ohms law [10].
Structure function studies revealed that rectification is
attributable to the charged amino acid at the inner mouth
of the ionic pore, as substitution of this charge renders the I-
V curve linear [18]. The high degree of conservation of this
biophysical property across receptor subtypes and different
animal species suggests a relevant functional phenomenon.
The importance of the rectification is easily understood
when considering the relationship between neurotransmitter
release and the transmembrane potential of the postsynaptic
neuron. Presence of acetylcholine will cause an inward
current in the receptors only if the cell membrane potential
is below −40 mV. Thus, activation of neuronal nAChRs
will have no significant effect if the cell is depolarized.
Altogether, this mechanism can be considered as a
coincidence detector in which the two conditions of
presence of the neurotransmitter and sufficiently negative
cell membrane potential must be fulfilled to elicit a
functional response.
Studies carried out in brain or spinal cord slices revealed
that a single neuron often expresses multiple receptor
subtypes that can be classified according to their physio-
logical and pharmacological properties (reviewed in [1]).
Importantly, however, receptors are not homogenously
distributed on the cell surface but are targeted to specific
cell locations. Targeting to subcellular compartments
depends upon multiple mechanisms in which the large
intracellular loop formed between the third and fourth
transmembrane segment plays an important role [54, 55].
Such discrete receptor expression has fundamental con-
sequences for the physiological role of nAChRs. For
example, it is readily understood that receptors expressed
on the cell soma will influence the cell resting potential and
thereby its firing threshold and frequency of discharges. By
opposition, receptors expressed on presynaptic boutons will
have no influence on the cell resting potential but can
regulate neurotransmitter release (reviewed in [13]). α7
nAChRs expressed on presynaptic endings have been
shown to regulate the intracellular calcium concentration
in these restricted subcellular compartments and modulate
the release of neurotransmitter contained in the vesicular
pool. Contrary to this, the α4β2 nAChRs expressed on
presynaptic nerve endings were shown to cause a local
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membrane depolarization which activates the voltage-
dependent calcium channels and, indirectly, modulates
neurotransmitter release. Albeit the functional outcomes of
homomeric and heteromeric nAChRs resemble each other,
their mechanisms of action clearly differ.
Physiological properties of mutated channels
Structure function studies of the nAChRs became possible
with the isolation of cDNAs encoding for the different
nAChRs subunits and their expression in host systems such
as Xenopus oocytes or cell lines [3, 39]. These pioneer
studies marked the first step towards the investigation of
human neuronal nAChRs and the influence of mutations on
the receptor function. Studies carried out with several
nAChR subtypes highlighted the role of the second
transmembrane domain, confirming the earlier hypothesis
that this domain borders the ionic pore. Insertion of a single
amino acid at the inner mouth of this transmembrane
segment was shown to be sufficient to convert the ionic
selectivity from cationic to anionic [21]. Largely confirmed
in further studies, this initial finding illustrated the
similarities in the structural organization and receptor
function amongst the family of cys-loop receptors, which
include the GABAA, glycine, and 5HT3 receptors. A single
amino acid exchange in this second transmembrane domain
caused obvious changes in receptor desensitization and was
interpreted as reflecting a modification in the gating of the
desensitized state [44].
The identification in 1995 of a first ADNFLE mutation
in CHRNA4, the gene encoding for the α4 nAChR subunit
marked an important step in our understanding of the
relevance of nAChRs in brain functions [49]. Affected
individuals from this family showed a missense mutation
causing the substitution of serine at location 248 by a
phenylalanine. As this mutation is in the second transmem-
brane domain, it was predicted that it might affect the
receptor properties. Functional studies carried out by
expression of this variant and the control β2 subunit indeed
confirmed that this mutation alters the receptor properties
[53]. While this mutation affects several properties of the
receptor, such as desensitization, and calcium permeability,
the relationship between this mutation and seizure suscep-
tibility is not immediately obvious [15, 32]. An interesting
clinical observation was that seizures and dyskinesia in
these patients were significantly reduced by the antiepilep-
tic drug carbamazepine. Based on this observation, func-
tional studies showed that the tricyclic compound
carbamazepine preferentially inhibits the mutated S248F
α4 containing receptors suggesting a correlation with the
clinical finding [42]. As initial experiments were carried out
by expression of the mutated α4 with β2, the experimental
conditions were not reflecting the patient's heterozygous
conditions with respect to the mutation. To get one step
closer to the physiological conditions, it was necessary to
examine if expression of a mutated α4 subunit shows
dominant effects when co-expressed with the wild type α4
and β2. Experiments carried out first in oocytes and then in
cell lines established the dominant nature of the S248F
mutant confirming that a single mutation can substantially
alter receptor function [6, 7, 28].
From the basic nature of the nAChRs, it was predicted
that mutations in either the gene encoding for the α4
subunit or the gene encoding for the β2 subunit could cause
identical changes in receptor function. Whilst at first, only
mutations in CHRNA4, which encodes the α4 subunit, were
identified, subsequent studies also discovered mutations in
CHRNB2, which encodes the β2 subunit [14, 40]. To date,
six mutations in CHRNA4 and five in CHRNB2 have been
found to be associated with ADNFLE. Providing a strong
support for the causality between the high affinity α4β2
nAChR and a specific form of epilepsy, these mutations
allow to search for a common alteration in receptor
properties that is responsible for seizure triggering. Func-
tional studies carried out in Xenopus oocytes with the
various ADNFLE mutations revealed their dominant
contribution when co-expressed with the control α4 and
β2 subunits and demonstrated that they all cause a gain of
function effect [4, 28, 30, 47]. Altogether, it was concluded
that either an increased acetylcholine sensitivity or a shift in
the proportion between low and high-sensitivity receptors is
the common trait linking together all mutations so far
identified in CHRNA4 or CHRNB2. Typical effects on the
acetylcholine concentration activation curve are shown in
the upper panel of Fig. 1.
While presenting the first evidences for the causality
between a mutation in a ligand-gated channel and epileptic
seizures, these studies also pointed out the naturally
occurring sequence variants that can be observed in many,
if not all, genes. As most nAChR subtypes are expressed in
the brain and the spinal cord, it would be of value to
examine the possible relationship between gene variants
and neurological disorders. The finding of an additional
form of nocturnal epilepsy that is caused by a mutation in
CHRNA2, the gene encoding for the α2 nAChR subunit,
further support the hypothesis that additional, so far
unknown, neurological disorders exist that are associated
with nAChRs. First identified in an Italian family, the
CHRNA2 mutation (I279N) was shown to cause an
increased sensitivity to acetylcholine [2]. In this initial study,
however, functional nAChRs were obtained only by expres-
sion of the α2 subunit with the β4 subunit and therefore
differed from the native receptors that most likely mainly
result from the assembly of α2 with β2. Further studies
carried out with the I279N α2 mutant expressed with the
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control β2 confirmed the gain of acetylcholine sensitivity
caused by this mutation together with additional modifica-
tions in the receptor properties such as a gain of sensitivity to
nicotine and in the carbamazepine blockade [29].
From a statistical point of view, it can be predicted that
mutations in α and β nAChR genes should have a
significant probability and might be found in the population
with a higher frequency of occurrence than those reported
up to now. In this respect, however, it should be
remembered that the biological marker, which allowed the
identification of the known mutants, is the clinical
phenotype of epilepsy. Mutations causing more subtle
effects in the receptor functions and therefore having lower
impact on the neuronal network properties have not yet
been identified in correlation with a clinical phenotype.
Mutations outside the channel domain
Looking at the distribution pattern of ADNFLE mutations,
it becomes obvious that they so far have only been found in
the rather small parts of the CHRNA4 and CHRNB2
subunits that contribute to the channel domain. However,
this does not necessarily implicate that mutations found in
Fig. 1 Autosomal dominant nocturnal frontal lobe epilepsy (ADN-
FLE)-associated modification of the nicotinic acetylcholine receptors
(nAChRs) and their putative effects on the brain network. Upper
panel: schematic representation of the receptor inserted into the
membrane and typical effects caused by a mutation in the β2 subunit
on the concentration activation curve. Plot represented in this figure
illustrates the relationship between the acetylcholine concentration and
the amplitude of the evoked response for the control α4β2 receptor
(blue triangles). Curve through the data point is the best fit obtained
with two Hill equations with a high and a low affinity. Note the wide
range for the acetylcholine concentrations. Effects caused by a point
mutation in the β2 subunit are illustrated by the red dot and curve (for
details, see Bertrand et al. [4]). Lower panel: representation of the
main components of the brain network that are supposed to contribute
to ADNFLE. Arrows illustrate the interactions between the thalamus
and the cortex with a negative feedback from the cortical thalamic
projections. The current hypothesis is that the gain of function of
α4β2 nAChR variants causes an unbalance of excitation versus
inhibition which in turn promotes seizure triggering
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future studies must also be restricted to this segment of the
protein. The pathophysiological effect of a given nAChR
mutation most likely depends more on the functional
pathways within the receptor to which the affected amino
acid participates in than on the actual localization of the
mutation within the subunit. This is possible because
contiguous structures link certain amino acids from the
channel domain to their functional counterparts within the
binding sites. The fact that the three principal mechanisms
of cys-loop receptors, i.e., agonist binding, coupling of
binding to gating, and gating, are linked by functional
pathways renders it possible that epilepsy might be caused
by mutations at amino acids outside the channel domains of
CHRNA4 and CHRNB2. Based on the current knowledge
of ADNFLE, such mutation should however result in a gain
of function, and it is possible to speculate where mutation
causing a gain of function might occur. First, and as noted
by Taly and Changeux [50], mutations affecting receptor
function are most likely to be found at the interface
between subunits. Second, mutations in the binding site
causing a gain of function must render the receptor more
sensitive to ACh. Structure function studies have already
shown that mutations in the N-terminal domain of the α or
β subunits can yield functional receptors that display a
higher sensitivity to ACh (D.B. personal data).
Screening for ADNFLE mutations should therefore not
be restricted to the transmembrane domain but must be
extended to the entire gene structure. However, it should be
kept in mind that mutations in different parts of nAChRs
might not cause necessarily exactly the same disorder but
some variant of it. It is possible that CHRNA4 or CHRNB2
not only harbor mutations that result in a gain but also ones
that cause a loss of function. It can be expected that the
clinical phenotypes caused by the latter class of mutations,
if they indeed exist, would not resemble ADNFLE but may
cause distinct type of neurological disorders. Further work
attempting to correlate receptor mutations with the physi-
ological modifications they cause and their possible
association with clinical phenotypes is therefore needed.
From receptor dysfunction to neuronal network
alteration
While functional studies carried out in expression systems
allow detailed physiological and pharmacological inves-
tigations, they can only provide predictions on the effects
on neuronal networks, and it is therefore indispensable to
examine the outcomes in animal models. Although several
laboratories attempted to produce mice models carrying
ADNFLE-like mutations, few genetically engineered mice
resulted in useful systems. Mice harboring a gain of
function mutation in L9′ of the α4 subunit (equivalent to
L247T initially described for the α7 subunit [44]) display a
higher sensitivity to nicotine-induced seizures than wild
type mice [16, 17]. Subsequently, knock-in mice were
engineered that carried the equivalents of human α4
ADNFLE mutations [31, 34, 51]. These mice presented
abnormal electroencephalography patterns, but only some
of them presented spontaneous seizures. The seizures could
be blocked by picrotoxin, an open channel blocker of the
GABAA receptors, and it was therefore suggested that
hypersynchronization was mediated by GABAergic neu-
rons [31]. In agreement with this hypothesis, it had been
documented that in the hippocampus, nAChRs can modu-
late the release of the neurotransmitter GABA and could
interact with interneurons [31, 36].
Introduction of the α4 mutation S252L in a transgenic rat
model (referred as S248L) yielded, however, different
conclusions. Contrary to mice, this rat model shows sponta-
neous epileptic seizures on arousal during slow-wave-sleep
(SWS) similar to those observed in ADNFLE patients.
Moreover, electrophysiological recordings carried out in brain
slices revealed two major abnormalities with a reduced
GABAergic synaptic and extrasynaptic transmission and
abnormal glutamate release during SWS [57]. The differences
observed between the mice and rat models suggest that
further analyses in different mammalian species is necessary
before reaching a conclusion about the multiple brain
dysfunctions caused by these point mutations and how they
cause epileptic seizures. A schematic representation of the
brain networks thought to participate in the epileptiform
activity is represented in the lower panel of Fig. 1.
Functional heteromeric receptors comprise of at least
two subunit subtypes such as in α4β2 nAChRs. As
receptors result from the assembly of five subunits, a single
receptor protein comprises a non-equivalent ratio of α and
β subunits. Differences in ratio between α and β have been
proposed to be at the origin of the high and low affinities
observed for the α4β2 nAChRs revealing the complexity of
these receptors even for two subunit compositions. Impor-
tantly, the number of possible combinations to form a
functional receptor differ for α and β subunits. Typically,
while α4 can combine either with β2 or β4 subunits, the
β2 subunit can combine with α2, α3, α4, α5, α6, and
putatively with the α7 subunit. This seems to suggest that
mutations in the α4 subunit might affect a more restricted
number of receptor subtypes than mutations in the β2
subunit. However, mutations in both the α4 and the β2
subunit cause the same epilepsy phenotype, which might
suggests that mutations in β2 only cause a neurological
phenotype when co-assembled with α4. Another possible
explanation would be that the epileptogenic effect only
occurs when mutant nAChRs are expressed in certain brain
structures in which the α4/β2 heteromeric receptor happens
to be the main nAChR.
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nAChRs and cognitive deficits
Although limited in number, data obtained from the
different families affected by ADNFLE reveal an associa-
tion between certain mutations and cognitive impairment
[11, 35]. Examples are the CHRNA4 mutation S252F that
co-segregates with mental retardation in two unrelated
families or the CHRNB2 mutation I312M which was found
in siblings that showed specific cognitive dysfunctions [4,
11, 27, 35]. The neuronal nAChRs are known to have an
important role in shaping synaptic connections and deter-
mining plasticity in brain areas involved in fundamental
aspects of cognition. It would therefore not be surprising if
future studies showed that the observed association be-
tween certain ADNFLE mutations and cognitive defects is
indeed a causative one. Until then, one has also to keep in
mind that the cognitive impairments might result from the
epileptic seizures themselves, and might therefore be only
indirectly related to the nAChR mutations. However, such
an indirect effect would hardly explain the observation that
other ADNFLE mutations, such as CHRNA4 S248F, are
almost never associated with cognitive defects. The latter
phenomena would be much easier to explain by a mutation-
specific effect. Such an effect would be likely to depend
somehow on the specific position of the mutated amino
acid within the receptor because neighboring mutations
such as S248F and S252F are discordant with respect to
their associations to cognitive defects. The mutation-
specific hypothesis is further supported by the so far only
known CHRNA2 mutation [2]. Experimental evidences
obtained from animal studies indicate that β2 containing
receptors participate in the signal elaboration in the
prefrontal cortex as well as other cortical areas [43]. As
α2 subunits are largely expressed in the prefrontal cortex of
higher mammals, it was proposed that receptors containing
α2 might participate in cognitive processing [24, 25].
However, the so far only known family harboring an
epilepsy-causing mutation in CHRNA2 does not display
major cognitive impairments. This could suggest either that
the epilepsy in this family is too benign to interfere with
higher brain functions or that it is just this specific α2
mutation that does not markedly affect cognitive processes.
Although all mutations identified so far result in a
receptor gain of function, it is also intriguing to speculate
about the putative effects of the above-discussed hypothetic
mutations that cause reduced receptor activity. Animal
experiments carried out with α4β2 antagonists such as
dihydro-beta-erythroidine or mecamylamine clearly indi-
cate that inhibition of this receptor subtype is detrimental.
This observation is in good correlation with the clinical data
observed in neurodegenerative disorders such as Alzheimer
where a preferential loss of the nicotinic receptor was
observed during the course of this disease. Loss of function
mutations are therefore at least as likely to interfere with
cognitive processes as gain of function mutations are
suspected to do.
While further work is required before obtaining a clear
relationship between nAChR and cognitive functions, these
studies underline the important role of nAChRs sequence
variants and prompt for more detailed studies of rare
mutations, common genetic variants, and cognitive capacities.
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